Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio –– Extends ...
In a bid to expand its reach in the attention-deficit/hyperactivity disorder (ADHD) market, Collegium Pharmaceutical has struck a deal to acquire Azstarys from Corium ...
BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and ...
CELEBRATION, Fla., Oct. 05, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced ...
Corium is having another crack at getting its weekly patch treatment for Alzheimer’s disease to market, securing a March PDUFA date a little more than one year after the FDA rejected its first try.
Corium International, Inc. CORI announced that it has entered a definitive merger agreement with a private investment firm, Gurnet Point Capital. Per this agreement, Gurnet will acquire Corium and ...
Corium International (NASDAQ: CORI) is down 11% at 11:58 a.m. EST after announcing that it priced $100 million of 5% convertible senior notes with an initial conversion price equivalent to ...
Corium International, Inc. CORI announced that it has entered a definitive merger agreement with a private investment firm, Gurnet Point Capital. Per this agreement, Gurnet will acquire Corium and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results